Hong Kong Stock Alert | 3D MEDICINES (01244) Surges Over 10% as Self-Developed Next-Generation Precision Nuclear Medicine Completes First Patient Dosing, Nuclear Medicine Market Shows Enormous Potential

Stock News

2025/09/09

3D MEDICINES (01244) surged over 10%, gaining 13.96% to HKD 9.06 at the time of writing, with trading volume reaching HKD 17.59 million.

On the news front, 3D MEDICINES recently announced that the first radioconjugate drug (RDC) from its proprietary nuclear medicine platform, 177Lu-PSMA-3D1015 injection, has completed first patient dosing in an investigator-initiated trial (IIT). The study aims to evaluate the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

According to data from MEDraysintell, the global nuclear medicine market is projected to reach nearly $39 billion by 2032. The company stated that 177Lu-PSMA-3D1015 injection has the potential to become a "best-in-class" nuclear medicine product, ultimately providing safer and more effective treatment options for prostate cancer patients worldwide, while advancing China's nuclear medicine R&D capabilities toward international leading standards.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1104268280"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1104268280\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1104268280?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-09 14:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104268280","market":"sg","top_or_hot":-1,"title":"Hong Kong Stock Alert | 3D MEDICINES (01244) Surges Over 10% as Self-Developed Next-Generation Precision Nuclear Medicine Completes First Patient Dosing, Nuclear Medicine Market Shows Enormous Potential","media":"Stock News","content":"<p>3D MEDICINES (01244) surged over 10%, gaining 13.96% to HKD 9.06 at the time of writing, with trading volume reaching HKD 17.59 million.</p>\n<p>On the news front, 3D MEDICINES recently announced that the first radioconjugate drug (RDC) from its proprietary nuclear medicine platform, 177Lu-PSMA-3D1015 injection, has completed first patient dosing in an investigator-initiated trial (IIT). The study aims to evaluate the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).</p>\n<p>According to data from MEDraysintell, the global nuclear medicine market is projected to reach nearly $39 billion by 2032. The company stated that 177Lu-PSMA-3D1015 injection has the potential to become a \"best-in-class\" nuclear medicine product, ultimately providing safer and more effective treatment options for prostate cancer patients worldwide, while advancing China's nuclear medicine R&D capabilities toward international leading standards.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Alert | 3D MEDICINES (01244) Surges Over 10% as Self-Developed Next-Generation Precision Nuclear Medicine Completes First Patient Dosing, Nuclear Medicine Market Shows Enormous Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Alert | 3D MEDICINES (01244) Surges Over 10% as Self-Developed Next-Generation Precision Nuclear Medicine Completes First Patient Dosing, Nuclear Medicine Market Shows Enormous Potential\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-09-09 14:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>3D MEDICINES (01244) surged over 10%, gaining 13.96% to HKD 9.06 at the time of writing, with trading volume reaching HKD 17.59 million.</p>\n<p>On the news front, 3D MEDICINES recently announced that the first radioconjugate drug (RDC) from its proprietary nuclear medicine platform, 177Lu-PSMA-3D1015 injection, has completed first patient dosing in an investigator-initiated trial (IIT). The study aims to evaluate the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).</p>\n<p>According to data from MEDraysintell, the global nuclear medicine market is projected to reach nearly $39 billion by 2032. The company stated that 177Lu-PSMA-3D1015 injection has the potential to become a \"best-in-class\" nuclear medicine product, ultimately providing safer and more effective treatment options for prostate cancer patients worldwide, while advancing China's nuclear medicine R&D capabilities toward international leading standards.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01244","symbol_name":"思路迪醫藥股份","start_time":0,"source_url":"","article_id":"1104268280","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104268280","pubTimestamp":1757397871,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"3D MEDICINES (01244) surged over 10%, gaining 13.96% to HKD 9.06 at the time of writing, with trading volume reaching HKD 17.59 million. On the news front, 3D MEDICINES recently announced that the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01244":"思路迪医药股份","BK1161":"生物科技"},"translate_title":"港股快讯|3D MEDICINES(01244)大涨超10%自研下一代精准核医学完成首例患者给药核医学市场展现巨大潜力","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01244":1},"content_text":"3D MEDICINES (01244) surged over 10%, gaining 13.96% to HKD 9.06 at the time of writing, with trading volume reaching HKD 17.59 million.\nOn the news front, 3D MEDICINES recently announced that the first radioconjugate drug (RDC) from its proprietary nuclear medicine platform, 177Lu-PSMA-3D1015 injection, has completed first patient dosing in an investigator-initiated trial (IIT). The study aims to evaluate the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).\nAccording to data from MEDraysintell, the global nuclear medicine market is projected to reach nearly $39 billion by 2032. The company stated that 177Lu-PSMA-3D1015 injection has the potential to become a \"best-in-class\" nuclear medicine product, ultimately providing safer and more effective treatment options for prostate cancer patients worldwide, while advancing China's nuclear medicine R&D capabilities toward international leading standards.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}